logo-loader
LON:AVCT

Avacta Group PLC

Receive alerts
Market:
LON
Market Cap:
£26.14 m
Price
£0.23
Change
-1.10%
52 weeks high
49.80
52 weeks low
21.00

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

Insight

Research

Avacta - interim results confirm progress

Avacta Group PLC (LON:AVCT) reported interim results t...

on 04/09/2019
Research

Avacta Group - Exciting partnership with Bach BioSciences

Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Bos...

on 07/30/2018
Research

Avacta Group - Rapid Progress of Immuno-oncology Programs

KEY INVESTOR MESSAGES Faster than expected development of the second immuno-oncol...

on 04/16/2018
Research

Avacta Group Plc - On track and undervalued

At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeuti...

on 01/24/2018